Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
12 p, 1.1 MB The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis / Egeberg, A. (Gentofte Hospital) ; Gisondi, P. (University of Verona) ; Carrascosa, Jose Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Warren, R.B. (Manchester NIHR Biomedical Research Centre) ; Mrowietz, U. (University Medical Center Schleswig-Holstein) ; Universitat Autònoma de Barcelona
Alterations in the innate and adaptive immunity underpin psoriasis pathophysiology, with the Th17 cells subset now recognized as the fundamental cells in the key controlling pathway involved in its pathogenesis. [...]
2020 - 10.1111/jdv.16273
Journal of the European Academy of Dermatology and Venereology, Vol. 34 (march 2020) , p. 1695-1706  
13 p, 3.0 MB Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks / Reich, K. (Dermatologikum Berlin) ; Warren, R.B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ; Iversen, L. (Aarhus University Hospital) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Pau-Charles, I. (Almirall R&D) ; Igarashi, A. (NTT Medical Center Tokyo) ; Ohtsuki, M. (Jichi Medical University) ; Falqués, M. (Almirall R&D) ; Harmut, M. (Almirall R&D) ; Rozzo, S. (Sun Pharmaceuticals) ; Lebwohl, M.G. (Icahn School of Medicine at Mount Sinai) ; Cantrell, W. (University of Alabama at Birmingham) ; Blauvelt, A. (Oregon Medical Research Center) ; Thaçi, D. (University of Lübeck) ; Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617  

Vea también: autores con nombres similares
1 Warren, Richard B.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.